NCT01259141 is a NA clinical trial of Moxifloxacin in Mycoplasma Pneumonia, sponsored by Capital Medical University.

Who is sponsoring NCT01259141?

NCT01259141 is sponsored by Capital Medical University.

What drugs are being tested in NCT01259141?

Interventions in NCT01259141: Moxifloxacin, Cephalosporins and azithromycin.

What condition does NCT01259141 study?

NCT01259141 studies Mycoplasma Pneumonia.

Is NCT01259141 still recruiting?

NCT01259141 is currently completed. Last updated 25 July 2015.

Last reviewed 2015-07-25 · How we verify

NCT01259141

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study

Completed NA Last updated 25 July 2015

What this trial tests

NA trial testing Moxifloxacin in Mycoplasma Pneumonia in 208 participants. Completed in 1 December 2014.

Timeline

1 October 2010

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	Capital Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	208
Start date	1 October 2010
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across China

Drugs / interventions tested

Moxifloxacin (moxifloxacin) — full drug profile →
Cephalosporins and azithromycin — full drug profile →

Conditions studied

Mycoplasma Pneumonia — all drugs for Mycoplasma Pneumonia →

Sponsor

Capital Medical University

Who can join

Adults 18 to 60, any sex, with Mycoplasma Pneumonia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to resolution of fever (defined as the period from start of study-drug to relief of fever)
Time frame: one month
usually duration of fever is about one to two weeks
Time to resolution of fever (defined as the period from onset to relief of fever)
Time frame: one month
usually duration of fever is about one to two weeks

Sponsor's own description

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Moxifloxacin

Trials testing the same drug.

NCT07513207 — A Study in Healthy People to Test How Vicadrostat Affects the Heart · Phase 1 · not yet recruiting
NCT07422298 — A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants · Phase 1 · recruiting
NCT07305831 — A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) · Phase 1 · active not recruiting
NCT07272629 — A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participan · Phase 1 · recruiting
NCT07229157 — Effect of Maridebart Cafraglutide on the Heart's Electrical Activity · Phase 1 · active not recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01259141 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 25 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01259141.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing